References 593 & 731. Moses H, 3rd, Matheson DH, Dorsey ER, George BP, Sadoff D, Yoshimura S. The anatomy of health care in the United States. JAMA. 2013;310:1947-1963. https://doi.org/10.1001/jama.2013.281425. 732. de Vries N, Boone A, Godderis L, Bouman J, Szemik S, Matranga D, et al. The Race to Retain Healthcare Workers: A Systematic Review on Factors that Impact Retention of Nurses and Physicians in Hospitals. Inquiry. 2023;60:469580231159318. https://doi.org/10.1177/00469580231159318. 733. Ministry of Health Welfare and Sport. Integraal Zorgakkoord. https://www.dejuistezorgopdejuisteplek.nl/. Accessed 4 December 2023. 734. Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, et al. Annual financial impact of welldifferentiated thyroid cancer care in the United States. Cancer. 2014;120:1345-1352. https://doi.org/10.1002/cncr.28562. 735. Kluijfhout WP, Pasternak JD, Lim J, Kwon JS, Vriens MR, Clark OH, et al. Frequency of High-Risk Characteristics Requiring Total Thyroidectomy for 1-4 cm Well-Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association. 2016;26:820-824. https://doi.org/10.1089/thy.2015.0495. 736. Dhir M, McCoy KL, Ohori NP, Adkisson CD, LeBeau SO, Carty SE, et al. Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. 737. Worrall BJ, Papachristos AA-O, Aniss A, Glover A, Sidhu SB, Clifton-Bligh RA-O, et al. Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update. Endocr Oncol. 2023;3:e220095. https://doi.org/10.1530/EO-22-0095 738. Tang AL, Kloos RT, Aunins B, Holm TM, Roth MY, Yeh MW, et al. Pathologic Features Associated With Molecular Subtypes of Well-Differentiated Thyroid Cancer. Endocrine practice. 2021;27:206-211. https://doi.org/10.1016/j. eprac.2020.09.003. 739. Semsar-Kazerooni K, Morand GB, Payne AE, da Silva SD, Forest VI, Hier MP, et al. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer. Journal of otolaryngology - head & neck surgery. 2022;51:9. https://doi.org/10.1186/s40463-022-00559-9. 740. Morand GB, Tessler I, Noik M, Krasner J, Yamin T, Pusztaszeri MP, et al. Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024. https://doi. org/10.1016/j.eprac.2024.01.002. 741. Barnes AB, Justice-Clark T, Li W, Randle RW. Molecular Testing for Indeterminate Thyroid Nodules: Association of Negative Predictive Value With Nodule Size. The American surgeon. 2022;88:2745-2751. https://doi. org/10.1177/00031348221109489. 742. Schenke SA, Campenni A, Tuncel M, Bottoni G, Sager S, Bogovic Crncic T, et al. Diagnostic Performance of (99m)TcMethoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter Study. Diagnostics. 2022;12. https://doi.org/10.3390/diagnostics12061358. 743. Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA otolaryngology - head & neck surgery. 2017;143:10151020. https://doi.org/10.1001/jamaoto.2017.1442. 744. Saravana-Bawan B, Bajwa A, Paterson J, McMullen T. Active surveillance of low-risk papillary thyroid cancer: A metaanalysis. Surgery. 2020;167:46-55. https://doi.org/10.1016/j.surg.2019.03.040. 745. Vuong HG, Le HT, Le TTB, Le T, Hassell L, Kakudo K. Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis. Pathology, research and practice. 2022;240:154180. https://doi.org/10.1016/j.prp.2022.154180. 746. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH. The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery. 2007;142:837-844; discussion 844 e831833. https://doi.org/10.1016/j.surg.2007.08.012. 747. Kizilgul M, Shrestha R, Radulescu A, Evasovich MR, Burmeister LA. Thyroid nodules over 4 cm do not have higher malignancy or benign cytology false-negative rates. Endocrine. 2019;66:249-253. https://doi.org/10.1007/s12020019-01964-3. 748. Baynes J, Dominiczak MH. Medical Biochemistry, second edition: Elsevier Mosby; 2004. 749. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. American journal of clinical pathology. 2008;130:736-744. https://doi.org/10.1309/AJCPKP2QUVN4RCCP. 750. Rossi ED, Faquin WC, Pantanowitz L. Cytologic features of aggressive variants of follicular-derived thyroid carcinoma. Cancer cytopathology. 2019;127:432-446. https://doi.org/10.1002/cncy.22136. 751. Ohori NP, Landau MS, Manroa P, Schoedel KE, Seethala RR. Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses. J Am Soc Cytopathol. 2020;9:213-220. https://doi.org/10.1016/j. jasc.2020.03.004.
RkJQdWJsaXNoZXIy MTk4NDMw